Alto Neuroscience, Inc. Operating Cash Flow
Alto Neuroscience, Inc. (ANRO) reported Operating Cash Flow of -$46.85 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- Alto Neuroscience, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$19.76M.
- Alto Neuroscience, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$27.09M.
- Alto Neuroscience, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$11.52M.
- Alto Neuroscience, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$9.92M.
- Alto Neuroscience, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$51.77M.
- Alto Neuroscience, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$47.42M.
- Alto Neuroscience, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$33.45M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$19.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$46.85M 10-Q · filed 2026-08-12 | -$58.37M derived: sum of 3 quarters · filed 2026-08-12 | -$68.28M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$27.09M 10-Q · filed 2026-05-13 | -$38.61M derived: sum of 2 quarters · filed 2026-05-13 | -$48.52M derived: sum of 3 quarters · filed 2026-05-13 | -$62.30M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$11.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$21.43M derived: sum of 2 quarters · filed 2026-03-16 | -$35.21M derived: sum of 3 quarters · filed 2026-08-12 | -$51.77M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$9.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$23.70M derived: sum of 2 quarters · filed 2026-08-12 | -$40.25M 10-Q · filed 2025-11-12 | -$53.27M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$13.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$30.34M 10-Q · filed 2026-08-12 | -$43.36M derived: sum of 3 quarters · filed 2026-08-12 | -$55.08M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$16.56M 10-Q · filed 2026-05-13 | -$29.58M derived: sum of 2 quarters · filed 2026-05-13 | -$41.30M derived: sum of 3 quarters · filed 2026-05-13 | -$53.00M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$13.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$24.75M derived: sum of 2 quarters · filed 2026-03-16 | -$36.44M derived: sum of 3 quarters · filed 2026-03-16 | -$47.42M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$11.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$23.42M derived: sum of 2 quarters · filed 2025-11-12 | -$34.40M 10-Q · filed 2025-11-12 | -$45.93M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$11.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$22.68M 10-Q · filed 2025-08-13 | -$34.20M derived: sum of 3 quarters · filed 2025-08-13 | -$41.97M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$10.98M 10-Q · filed 2025-05-14 | -$22.51M derived: sum of 2 quarters · filed 2025-05-14 | -$30.27M derived: sum of 3 quarters · filed 2025-05-14 | -$36.91M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$11.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$19.29M derived: sum of 2 quarters · filed 2025-03-20 | -$25.92M derived: sum of 3 quarters · filed 2025-03-20 | -$33.45M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$7.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$14.40M derived: sum of 2 quarters · filed 2024-11-12 | -$21.92M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$6.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$14.16M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | -$7.52M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |